🔗 Share this article

Given that the United States continues making historic revisions to its vaccination recommendations, one figure appears in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by casting doubt on coronavirus shots throughout the pandemic and has focused upon alleged deaths after Covid vaccination in her brief position at the Food and Drug Administration.

Proposed Overhauls to Childhood Immunization Program

Health officials had intended to unveil radical changes to the childhood vaccination calendar recently, synchronizing the US with the Danish vaccine program, sources say – a substantial departure that would put the US out of alignment with much of the global community with no evidence for benefit. The planned update has been pushed back until the new year.

In place of the director of the vaccine center, Høeg is set to present at the gathering. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the office this year.

A Shift at the Regulatory Body

The acting appointment may indicate a closer partnership between the drug and biologics divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

The new acting director has repeatedly called for discontinuing some childhood shot schedules in the US to become more in line with Denmark, a society with universal health coverage and a number of inhabitants roughly the population of the state of Wisconsin.

So far comments, she has continued to focus on vaccination policy – typically the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Expertise

The appointee has no apparent experience in pharmaceutical research, regulation or leadership, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the CDER, remarked a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in running a major agency. She is not an expert in drug approvals.”

Former commissioners of the center would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Clearly, she doesn’t have the type of experience that prior appointees who ran the center have had.”

The drug center has an immense workload at the agency, the former commissioner stated.

“Everybody just pays attention on the novel medication approvals, but the generic program authorizes a multitude of generic medications. There’s a biosimilars division, over-the-counter program and so forth, and all of those must be supervised,” Woodcock noted. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a major management aspect to the role, which oversees more than 5,000 personnel. “It is a huge leadership role, if you do it right,” the former official added.

Response and Disputed Programs

In response to concerns about Høeg’s qualifications and whether this selection signifies increased cooperation among agency officials on immunizations, a press secretary said that the “inquiries stem from flawed presumptions”.

“Her experience is consistent with the duties of her role,” the representative said, noting the period Dr. Høeg spent counseling the agency head on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s controversial expedited review system, a contentious rapid therapy clearance system that allegedly troubled her former heads. “By what process are these medications being selected for this expedited pathway? Who is making the decisions?” Howard asked. “There is a lot of lack of transparency going on at the agency right now.”

In general, he stated, “the agency seems to be moving towards more relaxed rules of most medications, with the exception of immunizations.”

Established Past Work on Immunizations

Concerning vaccines, Høeg has a clearer, if troubling, past, some experts said. She authored a analysis using unconfirmed volunteer-provided data to determine the incidence of heart inflammation following COVID-19 immunization. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccinations are more dangerous than they are.

Included in her “wish list” for the new government included altering regulations for recently developed shots and halting “non-essential” vaccines, she remarked after the election on a online show. At the FDA, Dr. Høeg has reportedly suggested excluding adolescent males from getting Covid vaccines.

“She’s an complete ideologue who begins with her conclusions and reverse-engineers to retrofit the evidence in a highly disingenuous, untruthful manner,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with fellow skeptics, {like|